Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.

Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, De Palma A, Mauri P, Monegal A, Rescigno M, Savino B, Colombo P, Jonjic N, Pecanic S, Lazzarato L, Fruttero R, Gasco A, Bronte V, Viola A.

J Exp Med. 2011 Sep 26;208(10):1949-62. doi: 10.1084/jem.20101956. Epub 2011 Sep 19.

2.

The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity.

Youn JI, Gabrilovich DI.

Eur J Immunol. 2010 Nov;40(11):2969-75. doi: 10.1002/eji.201040895. Review.

3.

Mechanism of T cell tolerance induced by myeloid-derived suppressor cells.

Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI.

J Immunol. 2010 Mar 15;184(6):3106-16. doi: 10.4049/jimmunol.0902661. Epub 2010 Feb 8.

4.

Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells.

Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S.

J Immunol. 2009 Jul 15;183(2):937-44. doi: 10.4049/jimmunol.0804253. Epub 2009 Jun 24.

5.

Catching cancer by the tail: new perspectives on the use of kinase inhibitors.

Khanna C, Gordon I.

Clin Cancer Res. 2009 Jun 1;15(11):3645-7. doi: 10.1158/1078-0432.CCR-09-0132. Epub 2009 May 26.

6.

Myeloid-derived suppressor cells: linking inflammation and cancer.

Ostrand-Rosenberg S, Sinha P.

J Immunol. 2009 Apr 15;182(8):4499-506. doi: 10.4049/jimmunol.0802740. Review.

7.

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.

Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH.

Clin Cancer Res. 2009 Mar 15;15(6):2148-57. doi: 10.1158/1078-0432.CCR-08-1332. Epub 2009 Mar 10.

8.

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.

Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC.

Cancer Res. 2009 Feb 15;69(4):1553-60. doi: 10.1158/0008-5472.CAN-08-1921. Epub 2009 Feb 5.

9.

Myeloid-derived suppressor cells as regulators of the immune system.

Gabrilovich DI, Nagaraj S.

Nat Rev Immunol. 2009 Mar;9(3):162-74. doi: 10.1038/nri2506. Review.

10.

Subsets of myeloid-derived suppressor cells in tumor-bearing mice.

Youn JI, Nagaraj S, Collazo M, Gabrilovich DI.

J Immunol. 2008 Oct 15;181(8):5791-802.

11.

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ.

Cancer Immunol Immunother. 2009 Jan;58(1):49-59. doi: 10.1007/s00262-008-0523-4. Epub 2008 Apr 30.

12.

Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives.

Rodríguez PC, Ochoa AC.

Immunol Rev. 2008 Apr;222:180-91. doi: 10.1111/j.1600-065X.2008.00608.x. Review.

13.

Translation of new cancer treatments from pet dogs to humans.

Paoloni M, Khanna C.

Nat Rev Cancer. 2008 Feb;8(2):147-56. doi: 10.1038/nrc2273. Review.

PMID:
18202698
14.

Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.

Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S.

Cancer Res. 2007 Oct 15;67(20):10019-26.

15.

Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer.

Biller BJ, Elmslie RE, Burnett RC, Avery AC, Dow SW.

Vet Immunol Immunopathol. 2007 Mar 15;116(1-2):69-78. Epub 2006 Dec 16.

PMID:
17224188
16.

The dog as a cancer model.

Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L, Breen M, Kitchell B, McNeil E, Modiano JF, Niemi S, Comstock KE, Ostrander E, Westmoreland S, Withrow S.

Nat Biotechnol. 2006 Sep;24(9):1065-6. No abstract available.

PMID:
16964204
17.

Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.

Serafini P, Borrello I, Bronte V.

Semin Cancer Biol. 2006 Feb;16(1):53-65. Epub 2005 Sep 15. Review.

PMID:
16168663
19.

Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.

Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI.

J Immunol. 2001 Jan 1;166(1):678-89.

20.

Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.

Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, Restifo NP, Zanovello P.

Blood. 2000 Dec 1;96(12):3838-46.

Supplemental Content

Support Center